New cancer drug BNT314 enters first human safety trial

NCT ID NCT06150183

Ongoing Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and tolerable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR

Contacts and locations

Locations

CHU de Liège

Liège, 4000, Belgium
Carolina BioOncology Institute, LLC

Huntersville, North Carolina, 28078, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Clinica Universidad de Navarra

Pamplona, 31008, Spain
GZA Ziekenhuizen

Antwerp, 2018, Belgium
Hospital Fund. Jiménez Dia

Madrid, 28040, Spain
Hospital HM Univ. Sanchinarro, Ensayos START

Madrid, 28050, Spain
Hospital Quironsalud Barcelona (NEXT Barcelona)

Barcelona, 08023, Spain
National Cancer Center Hospital East

Kashiwanoha, 277-8577, Japan
Northern Centre for Cancer Care

Newcastle, NE7 7DN, United Kingdom
Rigshospitalet

Copenhagen, DK-2100, Denmark
Royal Marsden Hospital - London

London, SW36JJ, United Kingdom
START Midwest

Grand Rapids, Michigan, 49546, United States
The Christie Hospital

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.